Doctors are applauding the remarkable effectiveness of a new treatment that completely eliminated tumors in cancer patients who had previously shown resistance to other therapies. A study conducted at the Institute of Cancer Research (ICR) in London revealed that the treatment resulted in tumor shrinkage for 42% of the participants.
Carl Walsh, a patient with severe tongue cancer, shared his experience of struggling with eating and speech due to the disease. He joined a study at The Royal Marsden Hospital in London, where a triple action cancer injection called amivantamab was being tested. The treatment showed unprecedented results by causing some patients’ tumors to vanish completely.
Amivantamab, administered every three weeks, targets the EGFR protein crucial for cancer growth, blocks the MET pathway used by tumor cells to resist treatment, and activates the immune system to attack the cancer cells. Patients like Carl, who did not respond well to chemotherapy and immunotherapy, saw significant improvements in their condition after receiving the treatment.
The trial, led by researchers at The ICR, involved patients with advanced head and neck cancer that had not responded to conventional treatments. Out of the patients who received amivantamab, 42% experienced tumor reduction, with 15 individuals achieving complete tumor disappearance.
Survival rates for patients on the drug averaged 12.5 months post-treatment initiation, offering hope to those with limited treatment options. Professor Kevin Harrington, an expert in cancer therapies, emphasized the substantial benefits of the treatment for patients with resistant cancers.
Amivantamab, manufactured by Johnson & Johnson, has already gained approval for certain lung cancer cases in the NHS. Ongoing clinical trials across the globe are assessing its effectiveness in various cancers, including lung, colorectal, brain, and gastric cancers.
The groundbreaking research, presented at the American Society of Clinical Oncology’s conference in Chicago, highlights the potential of innovative treatments in improving outcomes for patients facing challenging medical conditions.
